Twist Bioscience Corporation (TWST)

Market Cap	1.73B
Revenue (ttm)	362.27M
Net Income (ttm)	-85.19M
Shares Out	60.36M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,719,217
Open	27.96
Previous Close	27.45
Day's Range	27.82 - 29.58
52-Week Range	24.28 - 55.33
Beta	2.37
Analysts	Buy
Price Target	49.10 (+71.26%)
Earnings Date	Aug 4, 2025

About TWST

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 31, 2018
• Employees: 923
• Stock Exchange: NASDAQ
• Ticker Symbol: TWST
• Website: https://www.twistbioscience.com

Financial Performance

In 2024, Twist Bioscience's revenue was $312.97 million, an increase of 27.69% compared to the previous year's $245.11 million. Losses were -$208.73 million, 2.01% more than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $49.1, which is an increase of 71.26% from the latest price.

Price Target

$49.1

(71.26% upside)

Analyst Consensus: Buy